Meanwhile, CF scientific community also continues to develop novel cell models to more efficiently predict clinical efficacy and responsiveness [14,32,33,34,35], since conventional clinical trial designs are underpowered and impractical for rare CFTR mutations due to the very low number of individuals [30,36,37]. This evidence concerns the gene CFTR and cystic fibrosis.